论文部分内容阅读
目的 :评价 p糖蛋白 ( p170 )和多药耐药相关蛋白 ( m ultidrug resistance- associated protein,MRP)表达与急性白血病患者多药耐药的关系。方法 :将急性白血病患者按治疗效果分为初治敏感组、完全缓解组和复发难治组三组 ,用免疫细胞化学结合流式细胞仪测定 p170和 MRP。结果 :p170在各型白血病中完全缓解组均低于初治和复发难治组 ,MRP在 AML 中复发难治组明显高于完全缓解组 ;复发难治组 3 5人中 2 7例有上述两或一种蛋白表达增高 ,两者均与临床耐药相关。综合分析敏感性、特异性和准确性 ,以 p170和 MRP联合评价效果最佳。结论 :急性白血病多药耐药的发生是多因素的 ,p170和 MRP均与之有关
Objective: To evaluate the relationship between the expression of p-glycoprotein (p170) and multidrug resistance-associated protein (MRP) and multidrug resistance in acute leukemia patients. Methods: The acute leukemia patients were divided into three groups: naive sensitive group, complete remission group and refractory remission group. The levels of p170 and MRP were determined by immunocytochemistry and flow cytometry. Results: The complete remission group of p170 in all types of leukemia was lower than that of naive group and relapsed and refractory group. MRP was more common in patients with relapsed and refractory group than in complete remission group; 27 of 35 patients with relapsed and refractory group had the above Two or a protein expression increased, both with clinical resistance related. Comprehensive analysis of sensitivity, specificity and accuracy, p170 and MRP combined evaluation of the best. CONCLUSIONS: The incidence of multidrug resistance in acute leukemia is multifactorial, with both p170 and MRP associated with it